

Regd. Office :
1506, Chiranjiv Tower,
43, Nehru Place, New Delhi-110019
CIN No. : L74899DL1993PLC056594

Tel. : 011 - 47589500, 41608929
Tel. : 011 - 21800032
Fax : 011 - 26213081
Web : www.medicamen.com

Ref: STEX/Results/Published-2019-20

Date: 01.06.2019

The BSE Ltd
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001

Company Number: 531146

Sub. : Copy of Publication of Notice for Audited Financial Results for the Quarter and year ended 31st March, 2019

Dear Sir,

The Board of Directors at their Meeting held on 30.05.2019 adopted the Audited Financial Results of the Company for the quarter and year ended on 31st March, 2019

The copy of the results published in the "Financial Express" and "Jansatta" dated 31st May, 2019 is enclosed.

This is for your information and records.

Kindly acknowledge the receipt.

Thanking You,

Yours truly,
For Medicamen Biotech Limited



Parul Choudhary
Company Secretary
ACS-44157

Encl: As above.

sales nes to FY19



and an incentive of to 20,000 strong hybrid with an ex-factory price kh. ber last year, the com- ched its first lithium- ree-wheeler range Treo i to add to its fledgling for presentation, M&M proposed policy change EV 3W sales from 2025, est-in-class technology egment'. s to take Treo pan-India any further said it has orandum of understand- (Three Wheels United), a se providing affordable utorickshaw drivers and plying 1,000 units each oming year. n to push its EV venture, mber 2018 had opened hnology manufacturing h an investment of ₹100 luru. ew facility, its manufac- y for EVs would go up to ber annum.

Ericsson considering new clauses to av

PRESS TRUST OF INDIA
New Delhi, May 30

SWEDISH TELECOM GEAR maker Ericsson is considering tweaking provisions in busi- ness deals to avoid situations like those it is facing with Reliance Communications.

The company sued RCom and its pro- moter Anil Ambani to recover dues of about ₹1,500 crore, of which it managed to receive only ₹550 crore.

“We think fairness sort of came true in the end. But of course, as we sell new deals...we try to avoid those things. But it is

hard to tell becau that coming. That Laurin, senior vic business area mar told PTI.

He was resp whether the comp

M3 MEDICAMEN BIOTECH LTD.

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi- 110019
(CIN: L74899DL1993PLC056594) Website: www.medicamen.com
Email id: cs@medicamen.com

Extracts of Audited standalone Financial Results for the Quarter and Year ended on 31.03.2019 (In Lakhs)

Sl. No.	Particulars	Quarter Ended			Year Ended	
		Audited 31.03.2019	Un-audited 31.12.2018	Audited 31.03.2018	Audited 31.03.2019	Audited 31.03.2018
1	Total income from operations (net)	3,388.96	2,415.37	3,029.91	12,626.32	11,339.51
2	Net Profit/ (Loss) for the period (before tax, exceptional and/ or Extraordinary items)	421.72	365.59	377.12	1,771.19	1,390.00
3	Net Profit/ (Loss) for the period before tax (after exceptional and/ or Extraordinary items)	421.72	365.59	377.12	1,771.19	1,390.00
4	Net Profit/ (Loss) for the period after tax (after exceptional and/ or Extraordinary items)	283.94	240.45	186.24	1,221.49	1,011.27
5	Total comprehensive income for the period (Comprising Profit/ (loss) for the period (after tax) and other Comprehensive income (after tax))	283.94	240.45	186.24	1,221.49	1,011.27
6	Equity Share Capital	1,170.00	1,170.00	1,170.00	1,170.00	1,170.00
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)				7,493.36	6,290.79
8	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operation)					
	Basic:	2.43	2.06	1.66	10.44	9.03
	Diluted:	2.43	2.06	1.66	10.44	9.03

Note:

- The above results after being reviewed by the Audit Committee have been taken on record by the Board at its Meeting held on 30th May, 2019.
- The figures are regrouped in previous year also, wherever considered necessary.
- The Company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable.
- The Earning Per Share has been calculated as per IND AS-33.
- Auditor's Report has been carried out by the Statutory Auditors for the above period.

Place: New Delhi
Date : 30.05.2019

For Medicamen Biotech Limited
Sd/-
Rahul Bishnoi
Chairman

Regd. & Corporate Office
CIN : L45201DL1
E-mail :
Extract of Standalone and

S.No.	Particulars
1	Total income from operations
2	Net Profit / (Loss) for the period (before items)
3	Net Profit / (Loss) for the period before Extraordinary items
4	Net Profit / (Loss) for the period after Tax Extraordinary items
5	Total Comprehensive Income for the per period (after tax) and other Comprehen
6	Equity Share Capital
7	Reserves (excluding revaluation reserve of the previous year)
8	Earnings Per Share (of Rs. 5/- each) for - Basic (in Rupees) - Diluted (in Rupees)

Notes :

- The above financial results have been re 2019.
- The above is an extract of the detailed fi the Stock Exchanges under Regulati standalone and consolidated Finan (www.nseindia.com and www.bseind
- Ind AS 115, Revenue from Contract with has applied Ind AS 115 as on the transi that were not completed as at 1 April, standards has been de-recognised an period figures are not comparable to the On Standalone basis, profit amounting April, 2018 has been de-recognised an revenue from operations is higher by R were applicable. The basic and diluted On Consolidated basis, profit amounting April, 2018 has been de-recognised an revenue from operations is higher by R were applicable. The basic and diluted
- During the quarter under review the C Buildtech Private Limited from their exit
- Figures for the previous quarter/ period

Place: Delhi
Date: 29 May, 2019

MAGNACAST ELECTRO CASTINGS LIMITED

Regd. Office: 43, Balasundaram Road, Coimbatore - 641 018.
Email: magncast.com; Website: www.magncast.com CIN No: L31103T1990PLC002836

Audited Financial Results for the Quarter and Financial Year ended 31st March, 2019 (Rs. in Lakhs)

	Quarter Ended			Year Ended	
	31.03.2019	31.12.2018	31.03.2018	31.03.2019	31.03.2018
	3,270.32	3,168.85	2,597.02	12,587.59	9,462.99
Exceptional and / or	285.78	394.06	216.08	1,501.68	787.54
Exceptional Items	285.78	394.06	216.08	1,501.68	787.54

HARRISONS

CIN: L01119KL1978PLC0029
Willingdon Island, Cochin - 68200
Email id: secretarial@harrisonsmalaya

STATEMENT OF STANDALONE AND FOR THE QUARTER &

Sl. No.	Particulars



MEDICAMEN BIOTECH LTD.

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi- 110019
(CIN: L74899DL1993PLC056594) Website: www.medicamen.com
Email id: cs@medicamen.com

Extracts of Audited standalone Financial Results for the Quarter and Year ended on 31.03.2019 (In Lakhs)

Sl. No.	Particulars	Quarter Ended			Year Ended	
		Audited 31.03.2019	Un-audited 31.12.2018	Audited 31.03.2018	Audited 31.03.2019	Audited 31.03.2018
1	Total income from operations (net)	3,388.96	2,415.37	3,029.91	12,626.32	11,339.51
2	Net Profit/ (Loss) for the period (before tax, exceptional and/ or Extraordinary items)	421.72	365.59	377.12	1,771.19	1,390.00
3	Net Profit/ (Loss) for the period (before tax, exceptional and/ or Extraordinary items)	421.72	365.59	377.12	1,771.19	1,390.00
4	Net Profit/ (Loss) for the period after tax (after exceptional and/ or Extraordinary items)	283.94	240.45	186.24	1,221.49	1,011.27
5	Total comprehensive income for the period {Comprising Profit/ (loss) for the period (after tax) and other Comprehensive income (after tax)}	283.94	240.45	186.24	1,221.49	1,011.27
6	Equity Share Capital	1,170.00	1,170.00	1,170.00	1,170.00	1,170.00
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)				7,493.36	6,290.79
8	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operation)					
	Basic:	2.43	2.06	1.66	10.44	9.03
	Diluted:	2.43	2.06	1.66	10.44	9.03

Note:

- The above results after being reviewed by the Audit Committee have been taken on record by the Board at its Meeting held on 30th May, 2019.
- The figures are regrouped in previous year also, wherever considered necessary.
- The Company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable.
- The Earning Per Share has been calculated as per IND AS-33.
- Auditor's Report has been carried out by the Statutory Auditors for the above period.

For Medicamen Biotech Limited

Sd/-

Rahul Bishnoi
Chairman

Place: New Delhi
Date : 30.05.2019



Bharat Rasayan Limited

Regd. Office: 1501, Vikram Tower, Rajendra Place, New Delhi-110008.
CIN: L24119DL1989PLC036264

Email: investors.br@bharatgroup.co.in Website: www.bharatgroup.co.in

EXTRACT OF STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED MARCH 31, 2019 (₹ in lacs)

Particulars	Three months ended	Year ended	Three months ended
	31.03.2019 (Audited)	31.03.2019 (Audited)	31.03.2018 (Audited)
Total Income from Operations	27,223	99,218	19,344
Net Profit before Tax and Exceptional Items	3,932	15,690	3,242
Net Profit before Tax (after Exceptional Items)	3,756	15,514	3,835
Net Profit after Tax (after Exceptional Items)	2,941	11,153	3,552
Total Comprehensive Income (Comprising Profit/Loss after tax and other Comprehensive Income after tax)	2,924	11,134	3,569
Equity Share Capital [4248740 shares of ₹10/- each]	424.87	424.87	424.87
Reserves (excluding Revaluation Reserves) as per Audited Balance Sheet of previous year		-29,400	

पटाखा कारखाने में विस्फोट

विरुधुनगर, 30 मई। जिले में सत्तूर के मौत हो पास एक निजी पटाखा कारखाने में गुरुवार यह विस्फोट हो गया, जिसमें दो लोगों की मौत हो

डम्पी होल्डिंग्स लिमिटेड

CIN: L65993DL1982PLC078

पंजीकृत कार्यालय: 30, रजोकरी रोड, कापसहेड फोन नं. 9811641100, ईमेल: dumpyhold

डिविडेंड शेरधारकों के लिए

विषय: निवेशक शिक्षा एवं संरक्षा निधि प्राधिकरण (आईईपीएफ) कॉर्पोरेट कार्य मंत्रालय ("एमसीए") द्वारा 28 फरवरी, 2017 को अधिसूचित (लेखाकरण, लेखापरीक्षा, अंतरण एवं वापसी) नियम, 2016 ("आईईपीएफ" को धारा 124 के प्रावधानों के अनुसरण में, कंपनी को उन सभी शेरों ("आईईपीएफ प्राधिकरण") द्वारा डिपॉजिटरी भागीदार के साथ रखरखाव उच्चतम खाता ("आईईपीएफ उच्चतम खाता") में अंतरण करना आवश्यक लगातार सात या उससे अधिक वर्षों से लामांश का कोई दावा नहीं कि नियमों में निर्धारित विभिन्न आवश्यकताओं के अनुपालन में कंपनी ने उच्चतम खाते उनके नवीनतम पते पर व्यक्तिगत रूप से सूचित किया है जिनमें में अंतरित किये जाने के लिए उत्तरदायी है और ऐसे शेरधारकों का

क्र. सं.	शेरधारक का नाम	पिता/पति का नाम	घर
1.	श्री तपन कुमार रॉय	श्री ए कुमार रॉय	30 खास मोहारा 700006, पश्चिम बंगाल
2.	श्री टिकू वर्मा	श्री स्वदेश वर्मा	7 क्रिस्टियन पश्चिम बंगाल
3.	श्री कासोरी लाल पांडे	श्री सीता राम पांडे	18-बी, सत्या पश्चिम बंगाल
4.	श्रीमती अनीता सेन	श्री शीतल बोस	18-बी, सत्या पश्चिम बंगाल
5.	श्रीमती माया रानी गोयल	श्री रमेश गोयल	7 क्रिस्टियन पश्चिम बंगाल

यदि कंपनी को संबंधित शेरधारकों से 21 जून, 2019 या इसी कोई बड़ा है तो कंपनी आईईपीएफ नियमों के निर्धारित आवश्यकताओं के अनुपालन शेर प्रमाणपत्र जारी करके 25 जून, 2019 तक आईईपीएफ प्राधिकरण देगी और उसके बाद डिपॉजिटरी को डुप्लीकेट शेर प्रमाणपत्र को डिपॉजिटरी के पक्ष में अंतरण के बारे में कॉर्पोरेट कार्य मंत्रालय से बताया जा संबंधित शेरधारक यह नोट करे कि ऐसे अंतरण के बाद वह नियमों के आईईपीएफ प्राधिकरण के पास लामांश सहित कथित शेर(री) के संबंध अदायाकृत लामांश और उपरोक्त अनुसार अंतरित शेरों के संबंध में का इस संबंध में किसी भी पूछताछ के लिए आप कंपनी के उपरोक्त वर्णित पते पर लिखित में सम्पर्क कर सकते हैं।

स्थान: नई दिल्ली
तिथि: 30 मई, 2019

GOGIA CAPITAL

Registered Office: 100 A/1, The Capital
Audited Financial Results For t

Particulars

1	Income	
	(a) Revenue from operations	
	(b) Other operating income	
	Total revenue from Operations	
2	Other Income	
3	Total Income (1+2)	
4	Expenses	
	(a) Cost of materials consumed	
	(b) Purchases of stock - in trade	
	(c) Change in inventories of finished goods and work - in progress	
	(d) Excise duty on sales	
	(e) Employee benefits expenses	
	(f) Finance Costs	
	(g) Depreciation & Amortization Expense	
	(h) Other Expenses	
5	Total Expenses	
	Profit/ (Loss) before exceptional item and tax (3-4)	
6	Exceptional Items	
7	Profit/ (Loss) before tax (5-6)	
8	Tax Expenses	
	- Current Tax	